Skip to main content
PLUR
NASDAQ Life Sciences

Pluri Gets Nasdaq Delisting Warning — Must Reclaim $35M Market Value by January 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$1.63
Mkt Cap
$17.587M
52W Low
$1.59
52W High
$5.893
52W Position info
2.5% above low
Off High info
72% below high
Rel. Volume info
2.5× avg
Market data snapshot near publication time

PLUR is trading near its 52-week low of $1.59 (2.5% above the low) on elevated volume (2.5× avg).

Summary

Pluri received a Nasdaq delisting notice after its market value fell below the $35 million minimum. The company has until January 4, 2027 to regain compliance, but with a market cap of just $17.6 million and shares near 52-week lows, the path back is uncertain.


Key Events · Legal and Risk Events · PLUR

  • Nasdaq Delisting Notice Received

    On July 7, 2026, Pluri was notified it fails the $35 million market value of listed securities (MVLS) requirement, with a current market cap of approximately $17.6 million.

  • 180-Day Compliance Window

    The company has until January 4, 2027 to achieve a closing MVLS of $35 million or more for at least 10 consecutive business days.

  • Alternative Standards Also Unmet

    Pluri does not meet the alternative listing standards of $2.5 million in stockholders' equity or $500,000 in net income from continuing operations.

  • Delisting Risk Amid Liquidity Crisis

    The notice compounds existing distress: less than three months of cash runway, a $27.4 million EIB loan due, and recent emergency funding from the chairman.


Analysis · PLUR · Life Sciences

Nasdaq has formally warned Pluri that its market value has slipped below the $35 million minimum required for continued listing. The company now has 180 days to push its market cap back above that threshold for 10 consecutive trading days. With a current market cap around $17.6 million and shares trading near all-time lows, the path to compliance is steep — likely requiring a reverse stock split or a dramatic share-price recovery. This unfolds against a backdrop of acute cash shortages, a looming $27.4 million loan repayment, and recent emergency funding from its chairman. A delisting would severely impair liquidity and access to capital, compounding the company's survival challenges.

How filings like this one have moved

In the 30 days to Sep 10, 2026, 43.7% of the 583 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PLUR was trading at $1.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.6M. The 52-week trading range was $1.59 to $5.89. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PLUR - Latest Insights

PLUR
Aug 28, 2026, 9:21 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $1.50
Real-time Price: $1.37 info
Change: -$0.130 (-9%) info
Market Cap: $16.912M info
PLUR
Aug 28, 2026, 7:33 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.56
Real-time Price: $1.37 info
Change: -$0.190 (-12%) info
Market Cap: $16.912M info
PLUR
Aug 27, 2026, 8:03 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $1.47
Real-time Price: $1.37 info
Change: -$0.100 (-7%) info
Market Cap: $16.912M info
PLUR
Aug 17, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.60
Real-time Price: $1.37 info
Change: -$0.230 (-14%) info
Market Cap: $16.912M info
PLUR
Aug 17, 2026, 8:31 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $1.62
Real-time Price: $1.37 info
Change: -$0.250 (-15%) info
Market Cap: $16.912M info